Novartis’ Itvisma wins FDA approval as the first gene replacement therapy for spinal muscular atrophy (SMA) patients age 2 ...
This was not the first presentation on STI-571, but it was the one that would change everything: The New England Journal of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback